Methods of treating cancer using androgen receptor antagonists
AssigneeGarvan Institute of Medical Research
InventorsChristine Chaffer, Beatriz Pérez San Juan
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to cancer and methods of treating and diagnosing cancer.
Claims11
A method of sensitizing a cancer cell in a subject to an anti-cancer agent, comprising administering to the subject an androgen receptor antagonist, wherein the cell is a breast cancer cell, wherein the anti-cancer agent is docetaxel, paclitaxel, or doxorubicin, and wherein the androgen receptor antagonist is seviteronel.
A method of inhibiting the development of resistance to an anti-cancer agent in a cancer cell in a subject, the method comprising:
- determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cancer cell;
- and administering to the subject an androgen receptor antagonist if the level of expression and/or activity of the androgen receptor and/or ZEB1 is low, wherein the cell is a breast cancer cell, wherein the anti-cancer agent is docetaxel, paclitaxel, or doxorubicin, and wherein the androgen receptor antagonist is seviteronel.
A method of inhibiting the proliferation of a cancer cell in a subject, the method comprising:
- determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cancer cell;
- and administering to the subject an androgen receptor antagonist if the level of expression and/or activity of the androgen receptor and/or ZEB1 is high, wherein the cell is a breast cancer cell, wherein the anti-cancer agent is docetaxel, paclitaxel, or doxorubicin, and wherein the androgen receptor antagonist is seviteronel.
Dependencies are inferred from the claim text.